Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting

BACKGROUND: Anlotinib is a novel tyrosine kinase inhibitor with promising anti-tumor activity in patients with advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the efficacy and safety of anlotinib maintenance therapy in patients with advanced NSCLC in real-world sit...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jia, Han, Baohui, Liu, Huaimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282872/
https://www.ncbi.nlm.nih.gov/pubmed/35847883
http://dx.doi.org/10.3389/fonc.2022.785865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282872/
https://www.ncbi.nlm.nih.gov/pubmed/35847883
http://dx.doi.org/10.3389/fonc.2022.785865

Ejemplares similares